HER-2 Positive Breast Cancer Recruiting Phase 3 Trials for Eribulin (DB08871)

IndicationStatusPhase
DBCOND0042425 (HER-2 Positive Breast Cancer)Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs